Drug Trial Radar · NCT07576959
Effect of Bismuth Add-on to Dual Therapy for Helicobacter Pylori Eradication
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
990
Planned (sponsor's estimate)
Start
Apr 8, 2026
Primary completion
Dec 31, 2030
Study completion Dec 31, 2032
Sponsor
- Lead sponsor
- National Taiwan University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to compare the efficacy and safety of a bismuth-supplemented 14-day vonoprazan-based dual therapy ( triple therapy) versus a 14-day vonoprazan-based dual therapy without bismuth for first-line H. pylori eradication. Furthermore, the investigators will investigate the impact of these eradication regimens on the gut microbiota, the development of antibiotic resistance, and changes in metabolic syndrome indicators pre- and post-treatment.
Conditions
- HELICOBACTER PYLORI INFECTIONS
Interventions
Bismuth Add-on to Vonoprazan Dual TherapyDrug
bismuth, vonoprazan and amoxicillin for 14 days
Vonoprazan dual therapyDrug
vonoprazan and amoxicillin for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Eradication rate determined by Intention-to-Treat (ITT) analysisTime frame: 6-8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.